<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1072">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04667923</url>
  </required_header>
  <id_info>
    <org_study_id>002-NIV-COVID</org_study_id>
    <nct_id>NCT04667923</nct_id>
  </id_info>
  <brief_title>Noninvasive Ventilation in Moderate-to-severe COVID-19-associated Acute Respiratory Distress-syndrome</brief_title>
  <acronym>COVID-NIV</acronym>
  <official_title>Noninvasive Ventilation in Moderate-to-severe COVID-19-associated Acute Respiratory Distress-syndrome to Prevent Tracheal Intubation: the COVID-NIV Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>I.M. Sechenov First Moscow State Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>I.M. Sechenov First Moscow State Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-invasive ventilation can allow to avoid intubation and improve outcomes in&#xD;
      moderate-to-severe COVID-19-associated acute respiratory distress-syndrome (ARDS). Data on&#xD;
      NIV parameters adjustment based on expanded respiratory and gas exchange monitoring in&#xD;
      COVID-19 associated ARDS is limited. Appropriate adjustment of the inspiratory positive&#xD;
      airway pressure (IPAP) set as a point of the balance between minimal work of breathing&#xD;
      (minimum point of W.Patrick scale for assessment of the accessory respiratory muscles and&#xD;
      minimum diaphragm thickening fraction) and minimum tidal volume, and respiratory rate can&#xD;
      decrease NIV failure in moderate-to-severe COVID-ARDS. The objective of the study is to&#xD;
      evaluate the ability of non-invasive ventilation guided with expanded respiratory monitoring&#xD;
      to decrease the intubation rate in in moderate-to-severe COVID-ARDS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In December 2019, an outbreak of a novel coronavirus emerged in Wuhan, China and rapidly&#xD;
      spread worldwide. The World Health Organization (WHO) declared the outbreak a pandemic on&#xD;
      March 11th, 2020. The clinical disease (COVID-19) results in critical illness in about 5% of&#xD;
      patients with predominant acute respiratory failure.&#xD;
&#xD;
      The objective of the study is to evaluate the ability of non-invasive ventilation guided with&#xD;
      expanded respiratory monitoring to decrease the intubation rate in in moderate-to-severe&#xD;
      COVID-ARDS. Investigators will set IPAP as a point of the balance between minimal work of&#xD;
      breathing (minimum point of W.Patrick scale for assessment of the accessory respiratory&#xD;
      muscles, and minimum diaphragm thickening fraction) and minimum tidal volume, and respiratory&#xD;
      rate. Investigators will set expiratory pressure at 8-10 cm of water and the inspiratory&#xD;
      oxygen fraction (FiO2) to reach oxygen saturation by pulse oximetry (SpO2) 95%. All gas&#xD;
      exchange measurements will be set at IPAP level. For gas exchange assessment investigators&#xD;
      will measure partial oxygen tension in the arterial blood (PaO2), partial carbon dioxide&#xD;
      tension in arterial blood (PaCO2), end-tidal carbon dioxide tension (PetCO2), then will&#xD;
      calculate PAO2/FiO2, alveolar dead space (Vd alv) and ventilatory ratio (VR). Investigators&#xD;
      will measure expiratory tidal volume (VT), respiratory rate (RR), peak inspiratory flow (PIF)&#xD;
      and inspiratory time at 3 levels: at the set IPAP, at IPAP+4 cm of water and at IPAP-4 cm of&#xD;
      water. Measurements will be repeated on day 1, 3, 5, 7, 14 and 21 of NIV. NIV failure is&#xD;
      determined as one of the following at set IPAP 26 cm of water and FiO2 100%: fatigue, Patrick&#xD;
      scale 5 points, SpO2&lt;92%, apnoea, hemodynamic instability or Glasgow coma score &lt;14 points.&#xD;
&#xD;
      In patients with NIV failure after intubation and every 7 day after intubation investigators&#xD;
      will measure plateau pressure and calculate the driving pressure at PEEP 8-10-12-14 cm of&#xD;
      water and VT 6 ml/kg predicted body weight (PBW), and VT+100 ml and VT+200 ml at PEEP 8 cm of&#xD;
      water, plot static pressure volume-curve at positive end-expiratory pressure (PEEP) 5 and 14&#xD;
      cm of water, and perform electro impedance tomography.&#xD;
&#xD;
      This study is an observational trial in the ICU of the University hospital.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Intubation rate</measure>
    <time_frame>On day 28</time_frame>
    <description>Frequency of NIV failure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>On day 28</time_frame>
    <description>Mortality on day 28</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in arterial partial oxygen tension to inspiratory oxygen fraction (PaO2/FiO2) ratio</measure>
    <time_frame>Days 1, 3, 5, 7, 10, 14, 21 during noninvasive ventilation</time_frame>
    <description>Calculation of the arterial partial oxygen tension to inspiratory oxygen fraction (PaO2/FiO2) ratio using arterial oxygen tension measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ventilatory ratio</measure>
    <time_frame>Days 1, 3, 5, 7, 10, 14, 21 during noninvasive ventilation</time_frame>
    <description>Measurement of arterial carbon dioxide tension, minute ventilation and calculation of ventilatory ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in alveolar dead space</measure>
    <time_frame>Days 1, 3, 5, 7, 10, 14, 21 during noninvasive ventilation</time_frame>
    <description>Calculation of the alveolar dead space using end-tidal carbon dioxide measurement and arterial carbon dioxide tension measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in tidal volume</measure>
    <time_frame>Days 1, 3, 5, 7, 10, 14, 21 during noninvasive ventilation</time_frame>
    <description>Measurement of exhaled tidal volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in accessory respiratory muscles workload</measure>
    <time_frame>Days 1, 3, 5, 7, 10, 14, 21 during noninvasive ventilation</time_frame>
    <description>Calculation of the Patrick's scale (minimum 0 points, maximum 5 points, more points means worse outcome)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Covid19</condition>
  <condition>ARDS</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Respiratory monitoring</intervention_name>
    <description>Measurement of the tidal volume, peak inspiratory flow, inspiratory time, respiratory rate and the pressure gap during triggering on NIV and plateau pressure on mechanical ventilation</description>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Respiratory muscles ultrasound</intervention_name>
    <description>Measurement of the diaphragm thickening fraction, assessment of the contraction of scalene and sternocleidomastoid muscles</description>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Electro impedance tomography</intervention_name>
    <description>Measurement of the lung impedance changes in 4 quadrants, measurement of regional ventilation delay in 4 quadrants</description>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Capnography</intervention_name>
    <description>Measurement of end-tidal carbon dioxide tension</description>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Arterial blood gas</intervention_name>
    <description>Measurement of the oxygen partial pressure and the carbon dioxide partial pressure</description>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Quasistatic pressure-volume curve</intervention_name>
    <description>Quasistatic pressure-volume curve</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with COVID-19-associated moderate-to-severe acute respiratory distress-syndrome&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  at least one of the following criteria: fatigue, Patrick scale 5 points, SpO2&lt;92% on&#xD;
             standard oxygen therapy (&lt;15 l/min) or continuous positive airway pressure&#xD;
             (CPAP)-therapy with oxygen flow&lt;15 l/min&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  age less than 18 or more than 80 years&#xD;
&#xD;
          -  life-threatening heart rhythm abnormalities and/or systolic blood pressure &lt; 80 mmHg&#xD;
             despite norepinephrine at a dose &gt; 2 µg/kg/min&#xD;
&#xD;
          -  primary lung diseases (e.g. interstitial lung diseases, lung emphysema) or tumour&#xD;
             metastases in lungs&#xD;
&#xD;
          -  chronic decompensated diseases with extrapulmonary organ dysfunction (tumour&#xD;
             progression, liver cirrhosis, congestive heart failure)&#xD;
&#xD;
          -  Glasgow cona score &lt; 14&#xD;
&#xD;
          -  inability to swallow&#xD;
&#xD;
          -  upper airways obstruction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrey I Yaroshetskiy, MD, PhD, ScD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sechenov University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrey I Yaroshetskiy, MD, PhD, ScD</last_name>
    <phone>+79859900148</phone>
    <email>dr.intensivist@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sergey N Avdeev, MD, PhD, ScD</last_name>
    <phone>+79166145825</phone>
    <email>serg_avdeev@list.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sechenov University clinic #4</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikhail E Politov, MD, PhD</last_name>
      <phone>+79263711611</phone>
      <email>mikhail.politiv@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <reference>
    <citation>Avdeev SN, Yaroshetskiy AI, Tsareva NA, Merzhoeva ZM, Trushenko NV, Nekludova GV, Chikina SY. Noninvasive ventilation for acute hypoxemic respiratory failure in patients with COVID-19. Am J Emerg Med. 2021 Jan;39:154-157. doi: 10.1016/j.ajem.2020.09.075. Epub 2020 Oct 1.</citation>
    <PMID>33067061</PMID>
  </reference>
  <reference>
    <citation>Agarwal R, Handa A, Aggarwal AN, Gupta D, Behera D. Outcomes of noninvasive ventilation in acute hypoxemic respiratory failure in a respiratory intensive care unit in north India. Respir Care. 2009 Dec;54(12):1679-87.</citation>
    <PMID>19961634</PMID>
  </reference>
  <reference>
    <citation>Yaroshetskiy AI, Avdeev SN, Konanykhin VD. Acute Respiratory Distress Syndrome in COVID-19: Do All These Patients Definitely Require Intubation and Mechanical Ventilation? Am J Respir Crit Care Med. 2020 Nov 15;202(10):1480-1481. doi: 10.1164/rccm.202007-2713LE.</citation>
    <PMID>32809841</PMID>
  </reference>
  <reference>
    <citation>Patrick W, Webster K, Ludwig L, Roberts D, Wiebe P, Younes M. Noninvasive positive-pressure ventilation in acute respiratory distress without prior chronic respiratory failure. Am J Respir Crit Care Med. 1996 Mar;153(3):1005-11.</citation>
    <PMID>8630538</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 11, 2020</study_first_submitted>
  <study_first_submitted_qc>December 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2020</study_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

